

04-16-03

1625
A 4151.7 (2916/4)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

Art Unit 1625

APR 10 2003

TECH CENTER 1600/2900

Application of Gregory et al.

Serial No. 10/098,644

Filed March 15, 2002

Confirmation No. 7986

For IMMUNOSUPPRESSIVE EFFECTS OF ADMINISTRATION OF A
CYCLOOXYGENASE-2 INHIBITOR AND A 5-LIPOXYGENASE INHIBITOR

April 15, 2003

TO THE COMMISSIONER FOR PATENTS,


SIR:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit copies of the references listed on the attached PTO/SB/08A for consideration by the Patent and Trademark Office in the above-entitled application and to be made of record therein.

No item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing this document after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing of this Statement.

Respectfully submitted,



Kathryn J. Doty, Reg. No. 40,593
SENNIGER, POWERS, LEAVITT & ROEDEL
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KJD/rle

Express Mail Label No. EV 233499315 US